Factual · Independent · Patient-First

Your path through
cancer's complexity.

Explore every approved treatment, every open clinical trial, and every option your doctor might not know to mention — all in plain English, all in one place. Browse anonymously. No account required.

What cancer are you navigating?
22
Cancer types with full coverage
127
Clinical trials indexed from ClinicalTrials.gov
100%
Fact-based, source-cited data
Free
Always free to browse. Always.
A person walking a lit path through a dark maze, surrounded by floating medical information — representing the journey through cancer treatment options.
🔒 You are browsing anonymously.  No account needed to access treatment data, trial listings, or guides. Create a free account only when you're ready — to save your profile and opt in to trial matching.
A Note Before You Begin

If you're here, you're probably scared.
That's okay. You're in the right place.

You're likely here because you — or someone you love — is navigating a cancer diagnosis and trying to figure out what comes next. Maybe you've already spent hours searching and found nothing but statistics that terrified you and jargon written for doctors. That's exactly what this site was built to fix.

Your Cancer Path guides you through the full journey — starting with our Diagnostic Path, which walks you step by step through what tests should happen and in what order before any treatment begins. From there, our Care Pathways show how oncologists sequence treatment decisions, and our live clinical trial search surfaces every actively recruiting study matched to your cancer type. All of it in plain English. No hype. No agenda. Just facts.

🔬
Diagnostic Path
Step-by-step guide to what tests should happen, in what order, and what to watch out for — before treatment begins.
Live for 20+ cancers · More coming
🗺️
Care Pathways
How oncologists sequence treatment — first-line through escalation and salvage — so you understand every fork in the road.
Live for 20+ cancers · More coming
💊
Approved Treatments
Every FDA-approved drug with real efficacy data, side effect profiles, and the source trial — for all 22 cancer types.
All 20+ cancers live now
🧪
Clinical Trials
Live data from ClinicalTrials.gov — actively recruiting trials only, searchable by cancer type, drug, location, and sponsor.
Live data · Updated daily

This is not a substitute for your oncologist. But it will help you walk into that office better informed, with better questions, and a clearer picture of every option on the table. That's all we're trying to do.

KF
The Founder
Your Cancer Path · Cancer Survivor · 16 years cancer-free
How to use Your Cancer Path
Start anywhere. There's no wrong door.
1
Search or browse your cancer type
Use the search box above to find your cancer type instantly, or scroll down to browse all cancer types by card.
2
Start with Diagnostic Path if newly diagnosed
The 🔬 Diagnostic Path tab walks you through what tests to expect, what order they should happen in, and the watch-outs that could affect your results — before any treatment begins.
3
Explore treatments & care pathways
See every approved treatment with real efficacy data. The 🗺️ Care Pathways tab shows how oncologists sequence decisions — first-line through what happens if things change.
4
Search clinical trials & ask your doctor
Live trial data from ClinicalTrials.gov — actively recruiting only. Take what you find to your oncologist. Everything here is designed to make that conversation better.
🔒 No account required. Browse everything anonymously. No email. No sign-up. No tracking.
Find your cancer type

Select a cancer type below to explore every approved treatment, open clinical trial, and promising investigational drug — in plain English.

🔍
🔵
Prostate Cancer
The most common cancer in men. Highly treatable when caught early, with many options from active surveillance to surgery, radiation, and hormone therapy.
🧪 47 open trials
💊 12 approved treatments
🟡
Breast Cancer
Affects men and women. Highly nuanced — treatment depends heavily on hormone receptor status, HER2 status, and stage. Leronlimab and others show promise.
🧪 89 open trials
💊 21 approved treatments
🔴
Colorectal Cancer
Third most common cancer in the US. Increasingly affecting younger adults. Significant advances in immunotherapy and targeted therapies in recent years.
🧪 62 open trials
💊 16 approved treatments
🫁
Lung Cancer
NSCLC and SCLC. One of the most rapidly evolving oncology landscapes — immunotherapy and targeted therapy have transformed outcomes.
🧪 5 open trials
💊 10 approved treatments
🟠
Pancreatic Cancer
One of the most challenging diagnoses. New KRAS-targeted drugs and mRNA vaccines entering trials offer real hope for the first time.
🧪 5 open trials
💊 6 approved treatments
🟣
Lymphoma
Hodgkin and Non-Hodgkin. CAR-T cell therapies have dramatically changed outcomes for many patients in just the past decade.
🧪 5 open trials
💊 8 approved treatments
🩸
Leukemia
ALL, AML, CLL, CML and subtypes. Targeted therapies and CAR-T have transformed survival rates across multiple types.
🧪 5 open trials
💊 7 approved treatments
🖤
Melanoma
Immunotherapy has produced the most dramatic and durable complete responses ever seen in oncology — 40%+ long-term survival in metastatic disease.
🧪 5 open trials
💊 6 approved treatments
🟤
Bladder Cancer
Immunotherapy, antibody-drug conjugates, and FGFR inhibitors have transformed advanced urothelial carcinoma treatment.
🧪 5 open trials
💊 7 approved treatments
🫀
Ovarian Cancer
PARP inhibitors for BRCA-mutated patients and mirvetuximab ADC have transformed advanced disease — first OS benefit over chemotherapy now demonstrated.
🧪 5 open trials
💊 7 approved treatments
🫘
Kidney Cancer
Immunotherapy combinations have transformed advanced RCC — 40%+ of patients now achieve durable responses including functional cures.
🧪 5 open trials
💊 7 approved treatments
🦋
Thyroid Cancer
Most types are highly curable. Selective RET inhibitors and BRAF+MEK combinations have transformed medullary and anaplastic subtypes.
🧪 5 open trials
💊 7 approved treatments
🧠
Brain Cancer
IDH-targeted vorasidenib (2024 approval) marks a major advance for low-grade glioma. Tumor treating fields and personalized vaccines are reshaping GBM.
🧪 5 open trials
💊 6 approved treatments
🫙
Liver Cancer
Atezolizumab + bevacizumab replaced sorafenib after 13 years as standard of care — immunotherapy combinations producing the first meaningful OS improvements.
🧪 5 open trials
💊 6 approved treatments
🟫
Uterine / Endometrial
Immunotherapy for dMMR/MSI-H tumors is dramatically extending survival. HER2-targeted therapy for serous subtype. The most common gynecologic cancer.
🧪 5 open trials
💊 6 approved treatments
🔵
Multiple Myeloma
CAR-T therapies achieving 98% response rates and bispecific antibodies available off-the-shelf — the most exciting treatment landscape in all of blood cancer.
🧪 5 open trials
💊 7 approved treatments
🫶
Cervical Cancer
Pembrolizumab and tisotumab vedotin ADC have both shown OS benefit in advanced disease. HPV vaccination prevents most cases entirely.
🧪 5 open trials
💊 5 approved treatments
Esophageal Cancer
HER2, PD-L1, and CLDN18.2 testing now mandatory. Immunotherapy combinations standard first-line for metastatic disease across all histologies.
🧪 5 open trials
💊 6 approved treatments
🫐
Gastric / Stomach Cancer
HER2, PD-L1, CLDN18.2, and MSI testing all guide treatment. Nivolumab + chemo and zolbetuximab + FOLFOX are new first-line standards.
🧪 5 open trials
💊 6 approved treatments
🩺
Head & Neck Cancer
HPV status and PD-L1 CPS score guide first-line therapy. Pembrolizumab now standard. Tisotumab vedotin and LAG-3 inhibitors in advanced trials.
🧪 5 open trials
💊 6 approved treatments
🫁
Mesothelioma
Rare but aggressive cancer of the pleura and peritoneum, almost always linked to asbestos exposure. Nivolumab + ipilimumab now the frontline standard. BAP1, NF2, and CDKN2A drive emerging targeted approaches.
🧪 6 open trials
💊 4 approved treatments
🔶
Squamous Cell Carcinoma (Skin)
The second most common skin cancer — highly curable when caught early. Immunotherapy now transforms locally advanced and metastatic SCC, with 40-50% durable response rates to cemiplimab and pembrolizumab.
🧪 5 open trials
💊 5 approved treatments

✅ 22 cancer types now live

Browse every cancer type above, or use the Explore page to find treatments, open trials, and promising drugs for any diagnosis.

🧭
A note from the founder

I'm a prostate cancer survivor, and I built this because I lost a close friend to cancer last November — and spent months before that trying to help him find options the system never surfaced for him.

Clinical trials he qualified for. Expanded Access programs that were open and waiting. A drug the manufacturer was willing to provide. The information existed. We just couldn't get to it in time.

Your Cancer Path is my answer to that. Free. Anonymous. No agenda. Everything I wish we'd had — all in one place, in plain English, for every patient who deserves to walk into their next appointment knowing every option on the table.

☕ Support this mission
Built by a survivor.
For survivors and fighters.
📋

Factual Only. No Opinions.

Every treatment, side effect, and efficacy rate is sourced from FDA approvals, peer-reviewed studies, and ClinicalTrials.gov. We cite everything. This site is primarily U.S.-focused — international visitors should verify approval status with their local regulatory authority.

🔒

Anonymous First

Browse everything without creating an account. No email required. No tracking. Your health search is your business alone.

🧪

Trials at Your Fingertips

Every open, enrolling clinical trial pulled directly from ClinicalTrials.gov — filtered, simplified, and explained in plain English.

🤝

Real Patient Voices

Our community is moderated by cancer survivors who've been through it. Every post is reviewed before publishing. Real experiences, verified.

Prostate Cancer
Approved treatments, clinical trials, and promising investigational drugs
📋
Prepare for your appointment
Download a personalized question guide to bring to your oncologist  ·  Free  ·  1-page PDF
Sort by
Filter side effects
Min efficacy
🔍
No results found Try a different drug name, company, or keyword.
🗺️ Find Trials Near You — This Cancer Live from ClinicalTrials.gov

Enter your city to find actively enrolling trials near you. Results come directly from ClinicalTrials.gov — broader than the curated list below.

📍
📋 Curated Open Trials
Hand-selected key trials for this cancer
Checking ClinicalTrials.gov for live data…
Sort by
Phase
🔍
No trials found Try searching by drug name, company, sponsor, or NCT trial ID.

⭐ What are "Promising Drugs"?

These are drugs that have shown meaningful results in clinical trials but have not yet received full FDA approval. They may be available through clinical trial enrollment, compassionate use, or Right to Try. All data is factual and sourced from published trial results.

Let the right trial find you.
Clinical trial sponsors are actively looking for patients exactly like you. By creating a free profile and checking the box below, you can raise your hand — and we'll connect sponsors to you directly, through our platform. You stay in control at all times.
⚠️ You must create a free account to save this preference. You can change or remove your opt-in at any time. Your Cancer Path does not sell your personal health information. This opt-in is covered by our Privacy Policy and HIPAA-compliant data practices. Sponsors pay Your Cancer Path for platform access — not for your personal data.

🗺️ How to read these pathways

Care pathways show the typical sequence of treatment decisions — from first-line options through salvage and escalation if earlier treatments stop working. These reflect how oncologists generally think about sequencing, not a prescription for any individual patient. Always discuss your specific situation with your care team.

Where do you want to start?

Select a cancer type to explore every approved treatment, open clinical trial, and promising investigational drug.

🔍
🔵
Prostate Cancer
Most common cancer in men. Multiple treatment paths from watchful waiting to surgery, radiation, hormone therapy, and immunotherapy.
🧪 47 open trials
💊 12 approved treatments
🟡
Breast Cancer
Treatment depends heavily on subtype — hormone receptor status, HER2, stage, and genetic markers like BRCA all shape options.
🧪 89 open trials
💊 21 approved treatments
🔴
Colorectal Cancer
Colon and rectal cancers. Significant recent advances with immunotherapy for MSI-H tumors and targeted KRAS inhibitors entering the landscape.
🧪 62 open trials
💊 16 approved treatments
🫁
Lung Cancer
NSCLC and SCLC. Molecular profiling now guides targeted therapy selection — EGFR, ALK, KRAS G12C, MET, and HER2 are all actionable.
🧪 5 open trials
💊 10 approved treatments
🟠
Pancreatic Cancer
Challenging but evolving. BRCA testing matters. KRAS inhibitors and personalized vaccines are entering trials for the first time.
🧪 5 open trials
💊 6 approved treatments
🟣
Lymphoma
Hodgkin and Non-Hodgkin. CAR-T, bispecific antibodies, and BTK inhibitors have transformed outcomes for relapsed/refractory disease.
🧪 5 open trials
💊 8 approved treatments
🩸
Leukemia
ALL, AML, CLL, CML and subtypes. Targeted therapies including venetoclax, menin inhibitors, and CAR-T have reshaped survival expectations.
🧪 5 open trials
💊 7 approved treatments
🖤
Melanoma
The immunotherapy success story. Combination checkpoint blockade produces 40%+ long-term survival in metastatic disease — unthinkable a decade ago.
🧪 5 open trials
💊 6 approved treatments
🟤
Bladder Cancer
Urothelial carcinoma. FGFR testing, Nectin-4 ADC therapy, and enfortumab + pembrolizumab have transformed first-line metastatic disease.
🧪 5 open trials
💊 7 approved treatments
🫀
Ovarian Cancer
PARP inhibitors, mirvetuximab ADC, and bevacizumab combinations. FRa and BRCA testing guide treatment. First OS benefit over chemotherapy now demonstrated.
🧪 5 open trials
💊 7 approved treatments
🫘
Kidney Cancer
Immunotherapy doublets now preferred over single-agent targeted therapy. Belzutifan (HIF-2a inhibitor) is a new drug class for ccRCC.
🧪 5 open trials
💊 7 approved treatments
🦋
Thyroid Cancer
RET, NTRK, BRAF, and IDH testing define treatment for advanced disease. Most thyroid cancers cured with surgery and radioiodine.
🧪 5 open trials
💊 7 approved treatments
🧠
Brain Cancer
IDH mutation, MGMT methylation, and H3 K27M define treatment. Vorasidenib FDA approved 2024 — landmark for IDH-mutated low-grade glioma.
🧪 5 open trials
💊 6 approved treatments
🫙
Liver Cancer
HCC. Sorafenib replaced after 13 years by immunotherapy combinations. STRIDE regimen offers bevacizumab-free IO option.
🧪 5 open trials
💊 6 approved treatments
🟫
Uterine / Endometrial
MMR/MSI testing mandatory. dMMR tumors dramatically benefit from immunotherapy. HER2 testing for serous subtype. ADC therapies expanding.
🧪 5 open trials
💊 6 approved treatments
🔵
Multiple Myeloma
BCMA CAR-T achieving 98% ORR. GPRC5D bispecific (Talvey) approved 2023. Multiple new drug classes for relapsed/refractory disease.
🧪 5 open trials
💊 7 approved treatments
🫶
Cervical Cancer
Pembrolizumab for PD-L1+ disease. Tisotumab vedotin first ADC to show OS superiority over chemotherapy in recurrent cervical cancer.
🧪 5 open trials
💊 5 approved treatments
Esophageal Cancer
HER2, PD-L1, CLDN18.2 testing mandatory. Nivolumab or pembrolizumab + chemotherapy standard first-line across all histologies.
🧪 5 open trials
💊 6 approved treatments
🫐
Gastric / Stomach Cancer
HER2, PD-L1, CLDN18.2, MSI — four biomarkers define treatment. Zolbetuximab FDA approved 2024 as first CLDN18.2-targeted therapy.
🧪 5 open trials
💊 6 approved treatments
🩺
Head & Neck Cancer
HPV status and PD-L1 CPS score guide first-line therapy. Pembrolizumab now standard. Tisotumab vedotin and LAG-3 inhibitors in advanced trials.
🧪 5 open trials
💊 6 approved treatments
🫁
Mesothelioma
Rare but aggressive cancer of the pleura and peritoneum, almost always linked to asbestos exposure. Nivolumab + ipilimumab now the frontline standard. BAP1, NF2, and CDKN2A drive emerging targeted approaches.
🧪 6 open trials
💊 4 approved treatments
🔶
Squamous Cell Carcinoma (Skin)
The second most common skin cancer — highly curable when caught early. Immunotherapy now transforms locally advanced and metastatic SCC, with 40-50% durable response rates to cemiplimab and pembrolizumab.
🧪 5 open trials
💊 5 approved treatments
Trials currently enrolling patients

Live data pulled from ClinicalTrials.gov. Every trial listed is actively recruiting. Search by cancer type or keyword below.

💡 Only about 7% of cancer patients enroll in clinical trials

Most patients who qualify never find out about trials they're eligible for. Your Cancer Path was built to change that. Reading this page is the first step.

🔍
🔍
Live data from ClinicalTrials.gov
📍 Find Trials Near You

Enter your city to find actively enrolling trials within your area. Optionally filter by cancer type, drug name, or company. Results pull directly from ClinicalTrials.gov and include contact information for each site.

📍
Tools & Calculators

Clinical Tools for Patients

Scores and assessments your oncologist uses — explained in plain English so you can understand what they mean for your care.

🏃
ECOG Performance Status
Your oncologist uses this 5-point scale to determine which treatments you can safely tolerate. Select the description that best fits your current daily life.
🫁
IMDC Risk Score
For kidney cancer (RCC) patients considering systemic therapy. Check every factor that applies to you — your oncologist uses this to determine the best first-line treatment combination.
Check all that apply to you:
🔴
Child-Pugh Score
Measures liver function in patients with cirrhosis or liver cancer. Your hepatologist uses this to determine which treatments are safe. You'll need recent lab values (bilirubin, albumin, INR/PT).
Total Bilirubin (mg/dL)
Serum Albumin (g/dL)
INR (Prothrombin Time)
Ascites (Fluid in Abdomen)
Hepatic Encephalopathy (Confusion from Liver Disease)
📈
PSA Doubling Time (PSADT)
Calculates how quickly your PSA is rising — a key indicator of prostate cancer behavior after surgery, radiation, or on active surveillance. Requires two PSA values taken at least 3 months apart.
The earlier measurement — must be greater than 0.
The more recent measurement — must be higher than the first for a meaningful result.
R-ISS Staging — Multiple Myeloma
The Revised International Staging System combines three lab values with cytogenetics to determine prognosis and guide treatment intensity. You'll need your diagnosis labs (B2M, albumin, LDH) and FISH cytogenetics results.
Beta-2 Microglobulin (B2M) — mg/L Found on your myeloma workup labs. Normal is typically < 2.5 mg/L.
Serum Albumin — g/dL On your comprehensive metabolic panel (CMP). Normal is 3.5–5.0 g/dL.
Lactate Dehydrogenase (LDH) On your myeloma labs. Normal upper limit varies by lab — typically 250 U/L. Check if it was flagged as high.
FISH Cytogenetics Risk From your bone marrow biopsy FISH panel. High-risk = del(17p), t(4;14), or t(14;16). Ask your hematologist if you don't know your result.

⚠️ These tools are for education, not diagnosis

Clinical scores like ECOG are assigned by your oncologist based on direct observation — not self-report alone. Use these calculators to understand what the scores mean and to have better conversations with your care team, not to make treatment decisions independently.

How to access drugs
not yet FDA-approved.

The Right to Try Act (2018) and the FDA's Expanded Access program give seriously ill patients legal pathways to access investigational drugs that are not yet approved. Here's exactly how to pursue them — with real contacts, real forms, and real steps.

⚠️ Important Disclaimer

This guide is for informational and educational purposes only. It is not legal or medical advice. Your Cancer Path strongly recommends consulting with your oncologist and, where appropriate, a healthcare attorney before pursuing any of these pathways. Laws, eligibility requirements, and manufacturer policies vary by situation and may change.

🌍 Note for International Patients

The Right to Try Act and FDA Expanded Access programs described on this page are U.S.-specific legal pathways. Health Canada administers the Special Access Program (SAP). The European Medicines Agency (EMA) and individual EU member states have their own compassionate use frameworks. Australia's TGA offers the Special Access Scheme. Please speak with an oncologist in your country about locally available pathways.

Pathway Who Approves Timeline Best For
Clinical Trial IRB + FDA (ongoing) Weeks to enroll Best option if eligible — structured monitoring, no cost
Expanded Access EAP Manufacturer + FDA Days to weeks Drug has an open EAP program — contact sponsor directly
Individual Expanded Access Manufacturer + FDA (Form 3926) Days (24 hrs emergency) No open EAP — physician submits individual request to FDA
Right to Try Manufacturer only (no FDA) Varies by company Exhausted all options, cannot do clinical trial or EAP

These are manufacturer-sponsored programs that are currently open and accepting patients. Unlike clinical trials, EAPs don't require competitive enrollment — you contact the sponsor directly. This list is updated as programs are added to the site. Always verify current status directly with the sponsor before proceeding.

● Open — Accepting Patients
Leronlimab (PRO 140) — Triple-Negative Breast Cancer
🎗️ Triple-Negative Breast Cancer (TNBC) · Stage IIIB–IV
⚡ First patient dosed April 27, 2026 — this program is now actively enrolling. An Expanded Access Program providing leronlimab to TNBC patients who have progressed on prior standard-of-care therapy, are ineligible for SoC due to intolerance, or have no remaining standard options and cannot enroll in a clinical trial. Leronlimab is a humanized monoclonal antibody targeting CCR5, a receptor overexpressed in TNBC that drives metastatic spread and modulates the tumor microenvironment. New AACR 2026 data show CCR5 inhibition induces PD-L1 expression in TNBC — potentially sensitizing PD-L1-low tumors to immune checkpoint therapy. This is an intermediate-size population EAP managed by CRO partner WEP Clinical — meaning it is designed for a defined group of patients, not just a single individual.
Primary Janet Brockus — jbrockus@cytodyn.com  ·  360-980-8524
Backup Joe Meidling — jmeidling@cytodyn.com  ·  360-980-8524
Sponsor CytoDyn, Inc. (in collaboration with WEP Clinical)
Key eligibility requirements: Age ≥18 · Histologically confirmed HR-/HER2- metastatic TNBC (ASCO/CAP criteria) Stage IIIB–IV · Progressed on prior SoC or ineligible for SoC · ECOG performance status 0–2 · Not currently eligible for any leronlimab clinical trial · Must not have active untreated CNS metastases · Adequate organ and bone marrow function within 14 days of enrollment. Full eligibility criteria: clinicaltrials.gov/study/NCT07536815
NCT ID: NCT07536815 · Registered April 17, 2026 · Sponsor-verified contact information sourced from ClinicalTrials.gov registration

📬 Know of an open EAP we should list?

If you are a patient, caregiver, or sponsor with an open Expanded Access Program that should be listed here, contact us. We verify all listings against ClinicalTrials.gov or official FDA records before publishing. Our goal is to maintain the most complete and accurate EAP directory for cancer patients in the US.

If there is no open EAP for the drug you need, your physician can submit an individual patient Expanded Access request directly to the FDA. The FDA approves approximately 99% of these requests. For oncology, the dedicated Project Facilitate team can help your physician through the process within days.

1

Identify the drug and confirm you have no other options

Individual Expanded Access is for patients with a serious or immediately life-threatening condition for whom no comparable or satisfactory alternative therapy exists. Your physician must document that approved treatments have been tried or are not appropriate, and that you cannot participate in a clinical trial for this drug.

2

Your physician contacts the manufacturer first

Before submitting anything to the FDA, the drug manufacturer must agree to provide the drug. Your physician contacts the manufacturer's Medical Affairs or Compassionate Use department and requests a Letter of Authorization (LOA). This letter allows the FDA to reference the manufacturer's existing IND (Investigational New Drug application) — which means your physician doesn't need to submit all the underlying drug safety data. Without an LOA, the process is significantly more complex.

To find the manufacturer's Medical Affairs contact: search the drug name on navigator.reaganudall.org — the Reagan-Udall Foundation's Expanded Access Navigator includes a Company Directory with contact information for most manufacturers.

3

Physician submits FDA Form 3926 to Project Facilitate

Once the manufacturer provides an LOA, your physician submits FDA Form 3926 (Individual Patient Expanded Access — Investigational New Drug Application) along with the LOA to the FDA's dedicated oncology team. This is the form specifically designed for individual patient expanded access requests and is easier to complete than the standard IND forms.

FDA Oncology Project Facilitate — Direct Contact
Project Facilitate is staffed by oncology professionals who assist physicians with Expanded Access requests. They perform expedited reviews for oncology drugs. For emergency requests, FDA can authorize treatment by phone within 24 hours — the physician explains the situation and written submission follows within 15 business days.
4

IRB review — simplified for individual requests

Most expanded access requests require Institutional Review Board (IRB) review. However, Form 3926 includes a checkbox (Field 10.b) that allows your physician to request that IRB review be conducted by a single designated IRB member rather than the full committee — significantly speeding up the process. In emergency situations, treatment can begin before IRB review if the IRB is notified within 5 business days.

5

FDA issues authorization and treatment begins

Once the FDA completes its review — typically within days for non-emergency requests, 24 hours for emergencies — it issues a letter to your treating physician confirming the Expanded Access IND is approved and treatment may proceed. After informed consent is obtained, treatment can begin. Your physician will need to submit a summary of the treatment outcomes to the FDA at conclusion, and annual reports during ongoing treatment.

Right to Try is a federal law that bypasses the FDA entirely — the request goes directly to the manufacturer. The tradeoff is less oversight and no FDA safety review. Most oncology access advocates recommend trying FDA Expanded Access first, as it provides more structure and support. Right to Try is best used when FDA Expanded Access has been declined or is not available for a specific drug.

1

Confirm eligibility

Under the Right to Try Act, you must: (a) have a life-threatening diagnosis confirmed by a licensed physician; (b) have tried all approved treatment options or be unable to participate in a clinical trial; (c) be unable to enroll in a clinical trial for the specific drug. Your physician must certify all of this in writing. The drug must have completed at least Phase 1 safety testing and be in active clinical development.

2

Contact the manufacturer directly

No FDA involvement is required — the request goes directly to the drug manufacturer's Medical Affairs or Compassionate Use department. The Reagan-Udall Expanded Access Navigator (navigator.reaganudall.org) has a Company Directory with contact information. Be prepared to explain your diagnosis, treatment history, and why you are seeking this specific drug.

3

Physician submits a written request to the manufacturer

The manufacturer will require a letter from your treating physician confirming your diagnosis, prior treatment history, and clinical rationale for the request. Your physician must agree to monitor your treatment and document outcomes. Manufacturers are not required to provide the drug under Right to Try — but many will, particularly if you are a well-documented case that adds safety data to their ongoing program.

4

Understand the cost and coverage realities

Insurance typically does not cover Right to Try drugs. The manufacturer may provide the drug at no cost, at cost, or at compassionate pricing — policies vary significantly by company and situation. Ask the manufacturer explicitly about compassionate pricing and patient assistance. Some patient advocacy organizations can help fund access. Key resources: Patient Advocate Foundation 1-800-532-5274 · HealthWell Foundation 1-800-675-8416 · PAN Foundation 1-866-316-7263.

💬

A script for your next appointment

Many oncologists are unfamiliar with Expanded Access mechanics. Some may be hesitant. This is a reasonable conversation to initiate — your oncologist is your partner in this process and the FDA's Project Facilitate team is specifically designed to help physicians who have not done this before.

"I've been researching [drug name] and I understand it's currently in Phase [X] trials with promising results for my diagnosis. I'd like to explore whether I might be a candidate for FDA Expanded Access or an open Expanded Access Program. The FDA has a dedicated oncology helpline called Project Facilitate at 240-402-0004 or OncProjectFacilitate@fda.hhs.gov that can guide you through submitting Form 3926 — it's specifically designed for this and most requests are approved within days. Would you be willing to contact them on my behalf? I can bring you the manufacturer's contact information and the FDA form."
🏛️
FDA Project Facilitate (Oncology Expanded Access)
🧭
Reagan-Udall Expanded Access Navigator
navigator.reaganudall.org — Company directory, eRequest portal, Form 3926 guidance
📄
FDA Form 3926 — Individual Patient Expanded Access IND
Download directly from FDA.gov · Submit by email to Project Facilitate or via eRequest portal
🤝
Patient Advocate Foundation
1-800-532-5274 · patientadvocate.org — Financial assistance and case management for expanded access costs
📋
ClinicalTrials.gov Expanded Access Search
Search all open EAPs by condition — Filter by your cancer type and drug name to find currently available programs
Real experiences.
Verified voices.

Share your journey. Read others. Ask questions. Every post is reviewed by a volunteer moderator — a cancer survivor — before it goes live. You are not alone.

Coming Soon

A community moderated by survivors.
For survivors.

The Your Cancer Path community will be the first cancer support space where every post is reviewed by a fellow survivor before it goes live — not an algorithm, not a corporate moderation team. Real people who've been through it, keeping it honest and safe for everyone who comes after.

🙋
Survivor-Moderated
Every post reviewed by someone who's been there
🔒
Anonymous Option
Share without ever using your real name
Factual Standard
No miracle cures. No supplement sales. Ever.

Want to be notified when we launch — or volunteer as a founding moderator?

Moderation Notice: All posts are reviewed by volunteer survivor-moderators before publishing. This usually takes under 2 hours. Thank you for your patience.
?
Posting anonymously — create an account to use your name or handle.
📋 Select a topic tag:
K
✓ Survivor
I was diagnosed with cancer at 42, and I opted for surgery and I've been cancer-free for 16 years. But I remember the panic of those first weeks — searching the internet at 2am, finding conflicting information everywhere, not knowing what questions to ask my doctor. That's why this place exists. I built it for you. Ask anything. We'll do our best to help you find factual answers and connect you with people who've been through it.
M
Trial Participant
I'm currently enrolled in a Phase 2 trial for HER2+ breast cancer at UCLA. Three months in. I want to be honest — the process of getting into the trial was harder than I expected. My oncologist didn't know about it. I found it on ClinicalTrials.gov myself and brought the information to her. She was supportive once I showed her the data. The trial coordinator has been amazing. Happy to answer questions about what the enrollment process actually looks like from the inside.
R
Just finished my first cycle of FOLFOX. The fatigue is real. The neuropathy in my hands is something no one really warned me about. My oncologist was great but rushed — I wish someone had told me to ask specifically about cold sensitivity with oxaliplatin before I grabbed an ice-cold drink and felt like electric shocks in my fingers. Sharing this so someone else doesn't get surprised. Has anyone found anything that helped with the neuropathy?
Community Standards &
Terms of Participation

These rules exist to protect every person in this community. Please read them fully before participating.

⚖️ Attorney Review Notice: These community rules and terms have been drafted for attorney review prior to public launch. They are intentionally comprehensive to protect users, platform integrity, and legal compliance. If you are the attorney reviewing this document, please flag any sections requiring modification for HIPAA compliance, Section 230 protection, FDA disclaimer requirements, or state-specific regulations.

1. Purpose and Scope

Your Cancer Path is a research, education, and peer support platform for cancer patients, survivors, caregivers, and their families. It is not a medical practice, does not provide medical advice, and is not a substitute for consultation with a licensed physician or oncologist.

All information on Your Cancer Path is intended to help users become more informed participants in their own healthcare decisions — not to replace professional medical judgment.

Medical Disclaimer: Nothing on Your Cancer Path constitutes medical advice, diagnosis, or treatment recommendations. Always consult with your qualified healthcare provider before making any medical decisions. In a medical emergency, call 911 or go to your nearest emergency room.

2. Community Conduct Rules

All users — whether browsing anonymously or with an account — agree to the following standards when interacting with Your Cancer Path:

  • Be factual about your own experience. You may share what happened to you. You may not present your experience as applicable to others or as medical guidance.
  • Do not make medical claims about treatments. You may say "this drug made me feel X." You may not say "this drug cures cancer" or "this drug is better than what your doctor recommends."
  • No promotion of unproven or alternative cures. Claims that supplements, diets, spiritual practices, or unproven substances cure cancer will be removed. Sharing personal use of complementary therapies as part of your story is acceptable with appropriate framing.
  • No commercial promotion. You may not post affiliate links, promote products or services, advertise your practice or clinic, or solicit business of any kind.
  • Respect privacy. Never share another member's personal health information without explicit written consent. Do not attempt to identify anonymous users.
  • Be kind and constructive. Illness creates fear; fear creates sharpness. We ask for patience and empathy. Personal attacks, harassment, or bullying will result in immediate removal.
  • No misinformation. Do not post false or misleading information about treatments, clinical trials, or medical institutions. If you are unsure whether something is accurate, ask rather than assert.
  • No solicitation of personal contact outside the platform. Do not share your email, phone number, or solicit others' contact information in public posts. Use the platform's private messaging feature when available.

3. Moderation System

All posts submitted to Your Cancer Path go into a moderation queue before becoming publicly visible. Posts are reviewed by trained volunteer moderators — all of whom are cancer survivors or caregivers with lived experience.

Automated Red Flag System: Our platform uses keyword and pattern detection to pre-categorize posts:

  • 🔴 Red Flag (Auto-Hold, Priority Review): Posts containing miracle cure language, specific product promotion, pricing for medical services, claims that a drug "cures" any cancer, or references to obtaining prescription drugs illegally.
  • 🟡 Yellow Flag (Human Review Required): Posts containing strong efficacy claims about specific named drugs, references to Right to Try or off-label use, discussion of clinical trial access outside of enrollment, or emotionally intense content that may require sensitivity review.
  • 🟢 Green (Standard Queue): Personal experience sharing, questions to the community, emotional support, and general discussion.
Moderator Note: Volunteer moderators are empowered to Approve, Reject, or Escalate to a senior moderator or the Your Cancer Path team. Moderators are not medical professionals and do not evaluate medical accuracy — they evaluate compliance with community standards. Medical accuracy is handled at the platform content level by our medical advisory board.

4. Content Accuracy Standards

Treatment information, clinical trial data, drug efficacy figures, and side effect profiles published by Your Cancer Path on its treatment and trial pages are sourced exclusively from:

  • U.S. Food and Drug Administration (FDA) approved drug labeling and approval announcements
  • ClinicalTrials.gov trial registration data
  • Peer-reviewed published clinical trial results
  • National Cancer Institute (NCI) data
  • Published prescribing information (package inserts)

Your Cancer Path does not publish editorial opinions on treatment effectiveness. Where data conflicts between sources, we note the conflict and cite all sources. All content pages display their last review date and data source.

5. Trial Matching & Opt-In Data

Users who create an account and opt in to trial matching agree to the following:

  • Their profile data (cancer type, stage, treatment history, location) may be used to identify relevant clinical trial matches.
  • Matched trial sponsors may contact them through the Your Cancer Path platform only — personal contact information is never shared with third parties.
  • The opt-in can be removed at any time by updating account preferences.
  • Your Cancer Path does not sell personal health data. Sponsors pay for platform access, not individual data records.
  • All data is stored in HIPAA-compliant encrypted systems. [Attorney: Please review our data practices document separately for HIPAA compliance certification.]

6. Consequences of Violations

  • First violation: Post removed, private warning issued to account holder.
  • Second violation: Post removed, 7-day account suspension, written warning.
  • Third violation: Permanent account ban. Device and IP flagged.
  • Immediate permanent ban (no warnings): Promotion of illegal drug acquisition, harassment or threats, intentional medical misinformation likely to cause harm, sharing another user's private health information without consent, commercial spam or affiliate marketing.
Zero Tolerance: Any post that a reasonable person would interpret as promoting self-harm, discouraging evidence-based medical treatment in favor of unproven alternatives, or creating imminent risk of patient harm will result in immediate removal and permanent ban without appeal.

7. Volunteer Moderator Standards

Volunteer moderators agree to additional standards:

  • Review posts only against community standards — not personal medical opinion.
  • Maintain strict confidentiality of all content reviewed in the queue.
  • Escalate any post that raises a question of user safety, medical emergency, or platform liability.
  • Recuse themselves from reviewing posts from people they know personally.
  • Complete Your Cancer Path moderator training before reviewing any posts.
  • Commit to a minimum of 3 hours per week review time.

8. Right to Try & Expanded Access Content

Your Cancer Path provides educational guides on Right to Try and FDA Expanded Access. This content is:

  • Informational only — not legal or medical advice.
  • Sourced from the FDA, Right to Try Act (21 U.S.C. § 360bbb-0a), and official government resources.
  • Not an endorsement of any specific drug, manufacturer, or access pathway.

Your Cancer Path does not facilitate or arrange drug access on behalf of any user. We provide information to help patients advocate for themselves in partnership with their treating physician.

⚖️ Attorney Review — Terms of Service: The following Terms of Service are drafted for attorney review. Sections marked [ATTORNEY NOTE] require jurisdiction-specific review, including Section 230 applicability, HIPAA compliance, FDA disclaimer adequacy, California Consumer Privacy Act (CCPA) conformance, and enforceability of limitation of liability and arbitration clauses.

9. Terms of Service — Acceptance and Eligibility

By accessing or using Your Cancer Path (the "Platform"), whether as an anonymous visitor, registered user, community member, volunteer moderator, or any other capacity, you ("User") agree to be bound by these Terms of Service ("Terms"), our Privacy Policy, and our Community Rules, all of which are incorporated herein by reference.

If you do not agree to these Terms in their entirety, you must immediately discontinue use of the Platform. Your Cancer Path reserves the right to modify these Terms at any time. Continued use of the Platform following notice of modification constitutes acceptance of the revised Terms.

  • Age Requirement: You must be at least 13 years of age to use the Platform. Users under 18 must have parental or guardian consent. Your Cancer Path does not knowingly collect personal information from children under 13.
  • Geographic Scope: The Platform is operated from the United States. Users accessing the Platform from outside the United States do so at their own risk and are responsible for compliance with local laws.
  • Capacity: By using the Platform, you represent that you have the legal capacity to enter into binding agreements under applicable law.

10. Intellectual Property Rights

The Your Cancer Path name, compass rose logo, tagline "Find Clarity. Move Forward.", platform design, source code, written content, community guidelines, treatment data organization and presentation methodology, trial matching system, and all other original content on the Platform are the exclusive intellectual property of Your Cancer Path and its founder, Kelly Foy, protected by United States and international copyright, trademark, and trade secret laws.

Prohibited Conduct: You may not copy, reproduce, scrape, redistribute, create derivative works from, reverse engineer, sell, license, or otherwise exploit any portion of the Platform or its content without express prior written permission from Your Cancer Path. This prohibition applies to the Platform's design, code, written content, data organization, and community infrastructure — in whole or in part.

User-submitted content (posts, comments, testimonials) remains the intellectual property of the submitting user. By submitting content to the Platform, you grant Your Cancer Path a perpetual, worldwide, royalty-free, non-exclusive license to use, display, reproduce, and distribute such content in connection with operating and promoting the Platform, including in anonymized and aggregated research and marketing materials.

[ATTORNEY NOTE: Confirm DMCA safe harbor compliance, counter-notification procedures, and designated agent registration with Copyright Office.]

11. Privacy, Data Collection, and HIPAA

Your Cancer Path collects the following categories of information:

  • Anonymous browsing: Standard server logs, aggregate analytics. No personally identifiable information collected.
  • Registered users: Username, email address, cancer type, disease stage, treatment status, and geographic region (state/region only).
  • Opted-in users: All of the above plus additional health profile information voluntarily provided for trial matching purposes.
  • Community contributors: User-submitted posts, comments, and media, associated with your account.

Your Cancer Path treats all health-related user data as protected health information (PHI) and implements HIPAA-compliant administrative, physical, and technical safeguards. We do not sell your personal data. We do not share your personal contact information with pharmaceutical sponsors or any third party without your explicit consent. Sponsors may contact opted-in users only through the Platform's internal messaging system.

You have the right to access, correct, export, and delete your personal data at any time through your account settings. Requests can also be submitted to [email protected].

[ATTORNEY NOTE: Review full CCPA compliance requirements for California users, including opt-out rights, data deletion timelines, and annual disclosure obligations. Confirm HIPAA covered entity vs. business associate status. Prepare full Privacy Policy as a separate document.]

12. Clinical Trial Opt-In and Sponsor Matching

The trial matching and opt-in contact feature operates as follows:

  • Participation in trial matching is entirely voluntary. You may opt in or out at any time through your account settings.
  • By opting in, you authorize Your Cancer Path to share your anonymized health profile (cancer type, stage, treatment history, geographic region) with vetted clinical trial sponsors for the sole purpose of evaluating your potential eligibility for clinical trials.
  • Sponsors may send you a single introductory message through the Platform's internal messaging system. You control all further contact and may block any sponsor at any time.
  • Your Cancer Path charges sponsors a platform access fee. You are never charged for trial matching. Your Cancer Path does not receive compensation based on whether you enroll in a trial.
  • Trial matching is not a guarantee of eligibility, enrollment, or medical benefit. Eligibility is determined solely by the trial sponsor and your treating physician.
  • Your Cancer Path is not a healthcare provider, clinical research organization, or patient recruitment agency. We are an information and community platform that facilitates connections between willing patients and vetted researchers.

[ATTORNEY NOTE: Review FDA regulations on patient recruitment advertising (21 C.F.R. Part 312), FTC endorsement guidelines, and state-specific patient brokering laws. Confirm sponsor vetting standards and contractual requirements for platform access.]

13. Disclaimer of Warranties and Limitation of Liability

IMPORTANT — READ CAREFULLY: The Platform and all content, information, tools, features, and services provided thereon are offered "AS IS" and "AS AVAILABLE" without warranty of any kind, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose, accuracy, completeness, or non-infringement.

Your Cancer Path does not warrant that:

  • Treatment information, clinical trial listings, drug efficacy data, or side effect profiles are complete, current, or applicable to your specific medical situation;
  • The Platform will be uninterrupted, error-free, or free of viruses or other harmful components;
  • Any clinical trial you learn about through the Platform will accept you as a participant or produce a medical benefit;
  • Community member posts or testimonials are accurate, complete, or medically reliable.

To the maximum extent permitted by applicable law, Your Cancer Path, its founder, officers, advisors, moderators, and affiliates shall not be liable for any indirect, incidental, special, consequential, punitive, or exemplary damages arising from your use of or inability to use the Platform, including but not limited to medical decisions made in reliance on Platform content, loss of data, or unauthorized access to your account.

Your Cancer Path's total cumulative liability to you for any claim arising from these Terms or your use of the Platform shall not exceed the greater of: (a) the total fees paid by you to Your Cancer Path in the twelve months preceding the claim, or (b) one hundred dollars ($100.00).

[ATTORNEY NOTE: Confirm enforceability of liability cap under California law. Review consumer protection statutes that may limit disclaimer enforceability for health-related platforms.]

14. Indemnification

You agree to indemnify, defend, and hold harmless Your Cancer Path, its founder Kelly Foy, medical advisors, volunteer moderators, employees, contractors, and agents from and against any claims, liabilities, damages, losses, costs, and expenses (including reasonable attorneys' fees) arising out of or related to: (a) your use of the Platform; (b) your violation of these Terms; (c) your violation of any third-party rights, including intellectual property, privacy, or publicity rights; (d) any content you submit to the Platform; or (e) any medical decision you make based on information found on the Platform.

15. Governing Law, Arbitration, and Class Action Waiver

These Terms shall be governed by the laws of the State of California without regard to conflict of law principles. Any dispute arising from or relating to these Terms or your use of the Platform shall be resolved by binding arbitration administered by the American Arbitration Association under its Consumer Arbitration Rules, except that either party may seek injunctive or other equitable relief in any court of competent jurisdiction to protect intellectual property or confidential information.

Class Action Waiver: You agree that any arbitration shall be conducted solely on an individual basis and not as a class, collective, or representative action. You expressly waive your right to participate in any class action lawsuit or class-wide arbitration against Your Cancer Path.

[ATTORNEY NOTE: Review enforceability of mandatory arbitration and class action waiver under California law, including PAGA claims for employees. Confirm AAA Consumer Arbitration Rules are appropriate and that filing fees do not create unconscionability concerns.]

16. Section 230 and User-Generated Content

Your Cancer Path is an interactive computer service as defined under 47 U.S.C. § 230 (the Communications Decency Act). Your Cancer Path is not the publisher or speaker of user-generated content posted by community members and is not liable for such content to the extent permitted by Section 230. Your Cancer Path's moderation activities, including reviewing, approving, rejecting, or removing content, do not constitute editorial control that would eliminate Section 230 protections.

However, Your Cancer Path does not rely solely on Section 230 as a shield. We proactively moderate all content before publication to protect our community, and we will cooperate with law enforcement and regulatory authorities in response to lawful requests regarding Platform content.

[ATTORNEY NOTE: Confirm current Section 230 jurisprudence in the Ninth Circuit and any pending legislative changes. Review whether health-specific platforms face additional exposure under state consumer protection or health information statutes.]

17. Donations, Memberships, and Financial Transactions

Your Cancer Path accepts voluntary donations and Founding Member fees to support platform operations. All financial transactions are processed through third-party payment processors. Your Cancer Path does not store payment card information.

  • Founding Memberships are one-time, lifetime payments that unlock premium features. They are non-refundable except where required by applicable law.
  • Donations are voluntary contributions and are non-refundable. Whether donations are tax-deductible depends on Your Cancer Path's current tax status, which will be disclosed at the time of donation.
  • Angel and Visionary contributions are subject to separate written agreements. Contact [email protected] for details.

[ATTORNEY NOTE: Review IRS regulations on charitable solicitation, state charitable solicitation registration requirements (many states require registration before soliciting donations), and FTC endorsement rules for testimonials used in fundraising.]

18. Contact and Notices

All legal notices, attorney correspondence, DMCA takedown requests, privacy requests, and general inquiries should be directed to:

  • Email: [email protected]
  • Founder: Kelly Foy, Your Cancer Path
  • Location: Santa Ynez Valley, California
  • Website: yourcancerpath.com

Your Cancer Path will respond to properly submitted legal notices within 10 business days. For urgent matters involving user safety or potential harm, please indicate "URGENT" in your subject line.

Last Updated: April 2026 (Pre-Launch Draft — Pending Attorney Review)
Effective Date: Upon public launch (TBD)
Version: 1.0 MVP Draft

These Terms, Community Rules, and Privacy Policy collectively constitute the complete legal framework governing use of Your Cancer Path. Your Cancer Path reserves the right to update these documents at any time. Users will be notified of material changes via email (registered users) and platform banner notice (all users).

My Path

⭐ My Saved Items

Treatments and trials you've starred. Saved to this device — no account needed.

⭐ My Path 0
Built for my friend.
And for everyone who deserves better than what the system gave him.
"I've had my own experience with cancer. Years ago I faced a diagnosis that shook my world and opened my eyes to how hard it is to navigate the medical system when you're scared and don't know what questions to ask. I survived. I consider myself one of the lucky ones. But it was losing a close friend to cancer this past November that became the real catalyst behind Your Cancer Path."
The Founder, Your Cancer Path  ·  Cancer Survivor  ·  In memory of a friend who deserved more

He was someone I genuinely liked and admired — we first crossed paths in the 1990s, and when I found out about his diagnosis, something in me just couldn't stand by. I was determined to help him find every option available — not just the standard path, but everything. Clinical trials. Experimental drugs. Expanded Access. Right to Try. I believed then, and I believe now, that there were options worth exploring that might have given him more time.

What I found instead was a wall — not built by any one person, but by a system with layers of complexity that most patients and families have no idea exist.

He went through chemotherapy. He tried a targeted radiation therapy that made him miserable — the side effects were severe, and there were stretches where he was essentially confined to home because of how his body responded. He lost feeling in his feet. He was exhausted and in pain. And through all of it, he kept fighting.

I worked closely with him and his wife. I went to doctor's appointments with them. I tried to help navigate a path toward an investigational drug — one the manufacturer was willing and ready to provide. The drug company said yes. There was no guarantee it would have worked. But we wanted the chance to try.

What we ran into was the reality of how complex these pathways are. The paperwork. The liability concerns. The way our medical system is structured around standard of care — for reasons that aren't always wrong, but that can leave patients without options when time is short. His physician had real concerns, including around malpractice coverage, and I came to understand that those concerns are part of a bigger, broken system — not a reflection of any one doctor's heart. But in the moment, it felt like a door closing.

His wife didn't know these pathways existed. My friend didn't know. Most people don't — because nobody tells them. I reached out to physicians across the country trying to find someone who could help us move forward. A few pointed us in directions that required steps we couldn't complete in time.

My friend fought with everything he had. In the end, the cancer spread to his brain, his lungs, his entire body. He passed away in November. He is out of pain now. But I carry the weight of knowing that information and access existed that he never got to — and that we just couldn't connect him to it in time.

Your Cancer Path exists because of him. It exists for the patient who was just diagnosed and doesn't yet know what the road ahead might look like — what the diagnostic process involves, what questions to ask, and what options exist before treatment even begins. It exists for the patient already in treatment who wonders whether there is something else worth trying. It exists so that every patient — and their spouse, and their family — walks into every appointment knowing every option on the table. So they know what a clinical trial is and how to find one. So they know what Expanded Access means and how to start that conversation with their doctor. So they know that if one door closes, there may be others worth knocking on. I am not a doctor. This platform is not medical advice. But it is here, and it is free, and no one should have to navigate this alone.

Our Mission

To put factual, comprehensive, plain-English cancer treatment information in the hands of every patient and family who needs it — free, anonymous, and without agenda — so they can have better conversations with their doctors and find the right path faster.

Our Commitment

Your Cancer Path is independently operated. Pharma sponsors pay to reach our opted-in community — they do not pay to shape what we publish. Every fact is cited. Every source is disclosed. Our medical advisory board reviews all clinical content independently.

Stay Connected
Your Cancer Path is free. Always.
Browse every treatment, trial, and guide — no account needed, no sign-up, completely anonymous. We're currently in beta. If you'd like to stay informed about the full launch, share feedback, or learn about investment opportunities, we'd love to hear from you.
☕ Support this mission
Three Ways to Give

Choose what
feels right.

Your Cancer Path operates as two parallel entities — a technology company building the platform, and a nonprofit foundation ensuring free access for every patient who needs it. Your support funds both.

🏛️
How We're Structured

Your Cancer Path operates as two connected entities: Your Cancer Path Inc. (the tech company that builds and maintains the platform) and Your Cancer Path Foundation (the nonprofit that funds free access for patients who can't afford anything). Founding Memberships and Build Faster contributions go to the tech company. Fund a Fighter donations go directly to the nonprofit foundation. Full financial transparency is published quarterly.

🏥 Nonprofit Foundation
🤝
Fund a Fighter
Every dollar you give goes directly to the Your Cancer Path Foundation — keeping the platform free for patients who can't afford a premium service. When you give, you're not donating to a company. You're handing a compass to someone sitting alone in a guest room at midnight, scared and searching.
Select an amount
  • 100% goes to the nonprofit foundation — zero to platform operations
  • Tax-deductible once 501(c)(3) status is granted (in process)
  • Funds free access for patients, caregivers, and families
  • Optional: leave a dedication in memory of someone you love

Processed securely via Stripe. Receipt emailed automatically.

🏗️
Help Us Build Faster
Be specific with your support. Every dollar here goes directly to the infrastructure that makes Your Cancer Path trustworthy — attorney review, medical advisory fees, adding new cancer types, and technical development. We publish exactly how every dollar is spent.
$500
💼 One attorney review session — keeping the legal framework current and compliant
$1,000
🏥 One month of medical content review — an oncologist checks our work
$5,000
🧬 One new cancer type added to the platform — full treatments, trials, and pathways
$10,000
🌐 Three months of full development — new features, faster infrastructure, wider reach

Goes to Your Cancer Path Inc. (the tech company). Supports platform operations and growth.

Full Transparency

Your Cancer Path Foundation (Nonprofit)
  • • Free access funding for patients
  • • 501(c)(3) application in progress
  • • Quarterly financial reports published
  • • Zero admin overhead from Fund a Fighter donations
Your Cancer Path Inc. (Tech Company)
  • • Platform development and maintenance
  • • Attorney and medical advisory fees
  • • Founding Member benefits and features
  • • Portion donated to Foundation per membership
"I built this because I wish it had existed when my friend needed it. I'm one person. Every contribution — even a small one — means I can justify spending more hours on research, more cancer types, more pathways. It means someone somewhere finds the answer they needed. That's the whole point."
— Kelly Foy, Founder · Your Cancer Path · Santa Ynez Valley, California
Early Access

Stay connected.
Be part of what's coming.

Your Cancer Path is currently in beta. Whether you're a patient, caregiver, medical professional, or potential partner — we'd love to stay in touch as we build toward full launch.

⚠️
Early Access — Help Us Improve

The content on Your Cancer Path has not yet been reviewed by a licensed medical professional. All information is sourced from the FDA, ClinicalTrials.gov, and peer-reviewed publications, but please treat this as a starting point for conversations with your oncologist — not a substitute for professional medical advice.

Stay Connected with Your Cancer Path

Fill out the form below and we'll be in touch. We read every submission personally.

We respect your privacy. Your information will never be sold or shared. You can unsubscribe at any time.

Posts Pending Review

Review each post against community standards. Approve, reject, or escalate. You are not evaluating medical accuracy — only compliance with community rules.

Submitted 14 min ago · Prostate Cancer · Anonymous
Topic: Treatment Experience
🟡 Yellow Flag
"I used leronlimab off-label through a doctor in Mexico. My PSA dropped significantly after 3 months. I think everyone should know about this option. My doctor here in the US wouldn't prescribe it but I found a way to get it."
Flag reason: References obtaining a drug outside normal access channels, strong efficacy claim, and language that may encourage others to seek drugs illegally. Recommend escalation or rejection with personal experience reframe option.
Submitted 32 min ago · Breast Cancer · MargaretT
Topic: Clinical Trial Experience
🟢 Green
"Just completed month 4 of my Phase 2 trial. The fatigue has been manageable. The coordinator calls me every week. I feel like someone is actually paying attention to how I'm doing. For anyone considering a trial — the support structure is often better than standard of care in my experience."
Submitted 1 hr ago · Colorectal · Anonymous
Topic: General
🔴 Red Flag
"I cured my stage 4 colorectal cancer completely with high-dose vitamin C infusions and a ketogenic diet. My oncologist is shocked. I stopped all chemo 6 months ago. Anyone interested in more info, DM me, I sell a protocol guide for $197."
Flag reason: Miracle cure claim, commercial solicitation, discouragement of evidence-based treatment, off-platform contact solicitation. Recommend immediate rejection. Permanent ban review triggered.
🔒 Early Preview
Early Access — Help Us Improve. Medical content has not yet been reviewed by a licensed physician. Use this as a starting point for conversations with your oncologist — not a substitute for professional medical advice.
🧭
Welcome to Your Cancer Path
This is an early access of Your Cancer Path — a free platform built to help cancer patients and their families navigate treatment options and clinical trials.

Important: Content on this site is sourced from the FDA and ClinicalTrials.gov but has not yet been reviewed by a licensed medical professional. Everything here is intended to help you have better conversations with your oncologist — not to replace professional medical advice.
By continuing you acknowledge this is an informational resource only. Always consult your oncologist before making medical decisions.
Diagnostic Path
Which cancer were you diagnosed with?
Select your cancer type and we'll take you straight to the right section.
✓ PDF downloaded — find it in your Downloads folder to bring to your appointment
Suggest a Cancer Subtype
Can't find what you're looking for? Let us know and we'll consider adding it to Your Cancer Path. Your suggestion goes directly to our team.